Summit Therapeutics director Ujwala Mahatme resigns; annual meeting elects all eight nominees

Summit Therapeutics Inc.

Director Ujwala Mahatme resigned effective June 12, 2024, to focus on professional commitments; no disagreement with company.
At June 14 annual meeting, all eight director nominees elected with large majorities (e.g., Robert W. Duggan received 620.6M votes).
Stockholders ratified PwC as independent auditor for FY 2024 with 639.3M votes for and 39.8K against.
Non-binding advisory vote on executive compensation passed with 604.2M for, 15.9M against, and 18.9M broker non-votes.

item 5.02 item 5.07

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Ujwala Mahatme

Director

SMMT · Summit Therapeutics Inc.

Effective: 2024-06-12
Filed: June 17, 2024, 7:59 PM ET

Effective June 12, 2024, Ujwala Mahatme informed Summit Therapeutics Inc. (the “Company”) that she was resigning from her role as a member of the Board of Directors (the “Board”) of the Company, and from each committee of the Board, to focus on her increasing professional commitments outside the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Ujwala Mahatme resigned as Director at Summit Therapeutics Inc..

Action: resigned
Role: Director

Exact text from the filing

Effective June 12, 2024, Ujwala Mahatme informed Summit Therapeutics Inc. (the “Company”) that she was resigning from her role as a member of the Board of Directors (the “Board”) of the Company, and from each committee of the Board, to focus on her increasing professional commitments outside the Company.

View on SEC.gov

Summit Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-162715

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.